ArticleHuman vaccines & immunotherapeutics2019
Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines.
Article in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Rotavirus vaccine coverage, completion, and compliance: A systematic literature review.Human vaccines & immunotherapeutics · 2025Pooled it
- 15-year experience with rotavirus vaccination in Mexico: a systematic literature review.Human vaccines & immunotherapeutics · 2021Pooled it
- Rotavirus Infection as a Contributor to Early-Onset Type 1 Diabetes: Review and Recommendations.Viruses · 2026Review
- Epidemiology of Rotavirus and Its Association with Other Etiological Agents of Enteric Infections in the Mexican Child Population (0-5 Years).Microorganisms · 2026Article
- Health economic evaluation of 2-dose and 3-dose rotavirus vaccines in children below 5 years of age in Morocco.Human vaccines & immunotherapeutics · 2024Article
- Creating the vaccination improvement potential index.Heliyon · 2024Article
- Article
- Vaccination againstVaccines · 2023Article
- Cost-effectiveness analysis measuring the total costs against the health benefits of three different rotavirus vaccines for Mexico.Human vaccines & immunotherapeutics · 2023Article
- The Value of Rotavirus Vaccination in Europe: A Call for Action.Infectious diseases and therapy · 2023Article
- Established and new rotavirus vaccines: a comprehensive review for healthcare professionals.Human vaccines & immunotherapeutics · 2022Review
- Rotavirus vaccine administration patterns in Italy: potential impact on vaccine coverage, compliance and adherence.Human vaccines & immunotherapeutics · 2021Article
- Vaccines against gastroenteritis, current progress and challenges.Gut microbes · 2020Review
- Economic Evaluation of Human Rotavirus Vaccine in Thailand.Infectious diseases and therapy · 2019Article
- Vaccines for enteric diseases.Human vaccines & immunotherapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, rotavirus infection has been a leading cause of severe diarrhea morbidity and mortality. Two rotavirus vaccines have been used in the National Immunization Program (NIP) in Mexico; two-dose
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.